VKH
NVIV

Virtu KCG Holdings’s InVivo Therapeutics Holdings Corp NVIV Stock Holding History

Virtu KCG Holdings’s Portfolio NVIV Stock Details NVIV Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q2 		– Sell
-1
Closed -$126K – 3553
2016
Q1 		$126K Buy
+1
New +$107K ﹤0.01% 2265

Other funds holding NVIV

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
WF
Welch & Forbes Boston, Massachusetts $7.73B AUM 14.94% 1-Year Est. Return
BFA
BlackRock Fund Advisors San Francisco, California $542B AUM 18.13% 1-Year Est. Return
BIT
BlackRock Institutional Trust San Francisco, California $675B AUM 16.07% 1-Year Est. Return
SM
Sabby Management Miami Beach, Florida $45.1M AUM 74.25% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
ICM
IMS Capital Management Portland, Oregon $217M AUM 18.69% 1-Year Est. Return

Virtu KCG Holdings's NVIV Position: Q2 2016 in Review

Virtu KCG Holdings sold out of InVivo Therapeutics Holdings Corp (NVIV) in Q2 2016, closing a stake of 1 share — an estimated $126K sold.

Virtu KCG Holdings first reported a position in NVIV in Q1 2016 and held it in 1 quarter. The position peaked at $126K in Q1 2016. 44 funds tracked by Wall St. Rank hold NVIV as of Q2 2016.

  • Virtu KCG Holdings reported no remaining InVivo Therapeutics Holdings Corp position as of Q2 2016 after selling out during the quarter.
  • Virtu KCG Holdings sold 1 InVivo Therapeutics Holdings Corp share in Q2 2016, an estimated $126K.
  • Virtu KCG Holdings first reported a position in InVivo Therapeutics Holdings Corp in Q1 2016 and held it in 1 quarter.
  • Virtu KCG Holdings's InVivo Therapeutics Holdings Corp position peaked at $126K in Q1 2016.
  • 44 funds tracked by Wall St. Rank held InVivo Therapeutics Holdings Corp as of Q2 2016.

Based on Virtu KCG Holdings's 13F filing for Q2 2016, filed 12 Aug 2016.